Life Sciences M&A Surge Masks Pipeline Concerns, China Emerges as Key Target

Event summary

  • Global life sciences M&A activity reached US$240 billion in 2025, an 81% increase from US$130 billion in 2024.
  • The average deal size rose to US$2.1 billion, a 107% increase year-over-year.
  • China accounted for 34% of alliance investment in 2025, up from 4% in 2020.
  • Analysts project a US$370 billion growth gap by 2032, driven by patent expirations and geopolitical risks.
  • AI-related deals have seen a 256% increase in potential value.

The big picture

The surge in life sciences M&A reflects a desperate search for growth amidst looming patent cliffs and geopolitical uncertainty. While 'Firepower' remains abundant, the industry's reliance on large-scale deals and China for innovation signals a heightened risk profile. The increasing importance of AI in dealmaking highlights a potential shift towards data-driven acquisition strategies, but also underscores the challenges of integrating new technologies and achieving expected returns.

What we're watching

Execution Risk
The low success rate (32%) of deals achieving revenue targets suggests a need for more rigorous post-acquisition integration strategies, particularly as deal sizes increase.
China Exposure
The significant reliance on China for innovation and investment creates geopolitical risk; Western firms must balance opportunity with potential regulatory or political shifts.
Pipeline Pressure
The widening growth gap will likely intensify M&A activity, but whether companies can consistently identify and integrate targets to offset patent losses remains a key challenge.